cyrilzakka/clinical-trials huggingface dataset:
Validation of an Online Knee Pain Map and Questionnaire: A Probabilistic Diagnostic Tool

"Blank" has designed a medical diagnostic system in the form of an unvalidated online questionnaire and drawing tool used to describe and identify the location of knee pain, respectively. A component of the survey includes the patient inputting their diagnosis as the etiology of their knee pain. Dr. Ivo Dinov's team has used the data from 100,000 patient surveys to construct a probabilistic model to diagnose those who fill out the questionnaire and knee pain map but do not have a diagnosis. However, the validity of the online survey and the accuracy of the probabilistic model has not been confirmed in patients with known diagnoses. Therefore, the purpose of this study will be to recruit patients with knee pain at UCLA orthopedic clinics to complete the online survey which will then be applied to the probabilistic model to output possible diagnoses. The results will be compared to the actual diagnosis assigned to that patient in the clinic. If validated, the online survey may serve as a tool for diagnostic and research purposes.


Eligibility Criteria:
Inclusion Criteria:

* patients with knee pain and a known diagnosis for their pain
* patients older than 18 years old

Exclusion Criteria:

* patients that are unable or unwilling to complete the online survey.
* patients who do not have a diagnosis for their knee pain
4 Versus 6 cm Active Phase of Labour

A study to compare maternal and perinatal outcome between 4 and 6 cm cervical dilatation at amniotomy.

Low risk women with singleton pregnancy are recruited. There are two groups which are 4 and 6 cm cervical os dilatation. The intrapartum management and labour outcomes are documented.

Eligibility Criteria:
Inclusion Criteria:

* singleton pregnancy
* no medical disorders
* no antenatal complications such as hypertension and diabetes

Exclusion Criteria:

* fetal anomaly
* one previous caesarean section
* other uterine scars
Effect of Prebiotic Intake on Adiposity, Satiety and Gut Microbiota in Overweight and Obese Children

Currently, over one third of Canadian children and youth aged five to seventeen are overweight or obese. Childhood obesity leads to increased risks of co-morbidities such as type 2 diabetes, fatty liver disease, cardiovascular disease and certain types of cancers. Changes in the food supply have been linked to obesity and include a decrease in the intake of dietary fiber. Prebiotic fibers are a group of non-digestible carbohydrates that modulate the composition and actions of the gut microbiota and have been shown to reduce body fat and energy intake in overweight and obese adults. The investigators hypothesis is that prebiotic fiber intake in overweight and obese children will similarly result in improvements in body composition and reduced energy intake.

Obesity in the pediatric population is a primary public health concern given that overweight and obesity in childhood continues into adulthood. Consumption of high-fat, calorie-dense diets do not provide individuals with the suggested daily intake of many important nutrients. This is especially true for dietary fiber which has positive health benefits such as roles in weight management. A form of dietary fiber with links to obesity treatment/prevention is prebiotic fiber. In the gut, there are many bacteria which have been shown to affect a person's health depending on the type and number of each type of bacteria. The role of prebiotic fiber is to increase the number of beneficial bacteria which in turn promotes health. Studies in humans have shown that prebiotic fiber is effective at reducing body fat and food intake in overweight and obese adults. The aim of this study is to see if prebiotic fiber can provide the same benefits to overweight and obese children. Since weight management becomes increasingly difficult as a person ages, treatments that promote weight maintenance at an early age are critically needed.

Eligibility Criteria:
Inclusion Criteria:

* Boys and girls between the ages of 7-12 years old
* BMI percentiles \>85th percentile for their age and sex
* Tanner stage of ≤ 3, girls premenarche

Exclusion Criteria:

* Tanner stage of \>3 or girls postmenarchal
* Use of antibiotics up to 3 months prior to study
* Regular prebiotic supplement and/or probiotic supplement use
* Subjects unable to provide consent (parental) or assent (child)
Drug Eluting Balloon in Peripheral Intervention for In-Stent Restenosis

The purpose of this study is to evaluate the efficacy of drug-eluting balloon angioplasty followed versus conventional balloon angioplasty in superficial femoral artery and popliteal artery re-stenosis.


Eligibility Criteria:
Inclusion Criteria:

* age\>18 years
* intermittent claudication (Fontane III or IV)
* angiographic stenosis\>50% or occlusion of superficial femoral-popliteal artery\>40mm, previously treated with nitinol stent implantation, with at least one below-knee vessel to the ankle

Exclusion Criteria:

* allergy to Paclitaxel
* contraindication for combined antiplatelet treatment
* life expectancy \<1 year
* hypersensitivity or contraindication to one of the study drugs
* lack of consent
* need for amputation
* angiographic evidence of stent fracture
Distal Targeter vs Free-hand

This study is a randomized controlled trial comparing the use of two different surgical techniques--free-hand versus distal targeting jig-based for distal interlock screw--placement and their effects on total operative time and intraoperative radiation exposure.

Interlocking screw placement in intramedullary nailing of femoral and tibial shaft fractures improves rotational and length stability. However, free-hand perfect circle techniques can be technically challenging and may take up to an hour with increased radiation exposure to the surgeon and patient. Newer technologies aimed at reducing fluoroscope use such as electromagnetically-based aiming devices may increase the operative time. Proximally-based jigs have been shown to reduce fluoroscopy time in cadavers, however, have not been studied clinically. This study is a prospective, randomized controlled trial comparing a modern proximally-based distal targeting device and free-hand techniques for placement of interlocking screws in lower extremity nailing.

Eligibility Criteria:
Inclusion Criteria:

* 18 years old and above
* Undergoing intramedullary fixation of femur or tibia shaft for acute fracture or nonunion

Exclusion Criteria:

* Prior ipsilateral tibial or femoral nail
* Patients who cannot have interlocking screws placed
* Pregnant women
Study of a Tiotropium Inhaler For Shortness of Breath in Advanced Non-Small Cell Lung Cancer

The feeling of shortness of breath is very common in lung cancer. It is uncomfortable for patients and upsetting for their family. Although drugs like morphine and oxygen can help some patients feel better, they don't help everybody, and they are not used in patients with early symptoms. More relief is needed for these patients. The investigators are studying a drug called tiotropium, which is used in emphysema. It is an inhaler that opens the airways to allow easier breathing. Every patient will get the drug but also a placebo, in a random (flip of a coin) order. They will get each for 2 weeks. The investigators will see if they feel better with the drug.


Eligibility Criteria:
Inclusion Criteria:

1. Histologically or cytologically proven incurable stage IIIb or stage IV non-small cell lung cancer.
2. Dyspnea as defined by a score of 2 or higher on the 10-point Dyspnea Numeric Scale (Appendix 2).
3. New dyspnea or worsening dyspnea within the last 6 months per patient reporting.

Exclusion Criteria:

1. Age \< 18.
2. An FEV1 / FVC ratio \< 0.7 with an FEV1 of \< 80% predicted post-bronchodilator.
3. Life expectancy \< 3 months.
4. Significant worsening of dyspnea over the last week such that an acute cardiac or respiratory condition is considered likely (e.g. pneumonia, heart failure).
5. Myocardial infarction within the previous month.
6. Heart rate ≥ 120.
7. Active tuberculosis or tuberculosis receiving antibiotic therapy.
8. Current or previous use of ipratropium, tiotropium, or oxitropium (see Appendix 6).
9. Sensitivity to atropine.
10. Pre-existing diagnosis of asthma or moderate to severe Chronic Obstructive Pulmonary Disease
11. Use of beta-adrenergic bronchodilators more than once per week.
12. Use of experimental therapy with known cholinergic or adrenergic effects.
13. Uncontrolled glaucoma.
14. Urinary retention.
15. An active upper or lower respiratory infection or having taken antibiotics for any recent respiratory infection within 4 weeks.
16. Symptomatic pleural or pericardial effusion.
17. Evidence of reversible proximal endobronchial obstruction.
18. Oxygen saturation \< 90%.
19. A hemoglobin of \< 100 g/litre. Testing is to be within 4 weeks of randomization.
20. Calculated or urine creatinine clearance ≤ 50 mL/min (see Appendix 5 for calculation). Testing it to be within 4 weeks of randomization.
21. Weight loss \> 10% of usual body weight within 6 months.
22. Known pregnancy or lactating.
23. Unable to independently fill out quality of life forms or give informed consent.

    -
Salt Iodization: Meeting the Needs of Pregnancy, Lactation and Infancy

The purpose of this study is to determine whether universal salt iodization (USI) meets the iodine requirements of pregnant women, lactating women and infants.

Because pregnant women, lactating women and infants are the groups most vulnerable to iodine deficiency and its irreversible consequences, programs should focus on these groups. But like other mass fortification strategies, it is uncertain whether USI can meet the increased dietary requirements of pregnant women, lactating women and infants. Objective of this study to test whether USI can meet the dietary requirements of iodine in women of reproductive age, pregnant women, lactating women and infants up to 2 years of age without causing excess iodine intake in school children and non-pregnant non-lactating women. The study hypothesis is that USI, when fortified at adequate levels and applied to all salt consumed, including both household salt and salt used for processed foods, provides adequate dietary iodine for all population groups, except for weaning infants; while not posing any risk of excessive iodine intakes in other age groups.

Eligibility Criteria:
Inclusion Criteria:

* living at study area for at least 6 months
* generally healthy
* no chronic medication
* no history of thyroid disease in the family
* no use of iodine containing dietary supplements during the last 6 months
* no use of iodine containing disinfectants for the last 6 months
* no use of X-ray / CT contrast agent or iodine containing medication within the last year
* in addition for women of reproductive age, pregnant women and breastfeeding women: age between 18 and 44 years old
* in addition for pregnant women: healthy pregnancy, singleton pregnancy (no twins or multiple pregnancy)
* in addition for breastfeeding women and breastfed infants: healthy pregnancy, singleton pregnancy (no twins or multiple pregnancy), baby born at full-term (in pregnancy week 38 to 42), the baby had normal birth weight (≥ 2500 g), baby not older than 6 months, baby currently completely breastfed (except for water, tea and juices)
* in addition for toddlers: between 6 and 24 months old
Tracking Biomarkers of Speech Intelligibility

Difficulties understanding speech in noisy environments repeatedly coincide with high-frequency hearing loss. This complaint is commonly exhibited in adults in middle/older age who have a history of noise exposure. In this study, an immersive audiomotor training game will be utilized to drive improvements in speech intelligibility, controlled by an auditory memory training game. Physiological measures will be tracked that could inform clinical assessment of hearing in noise abilities.

Hearing loss is a chronic health disorder affecting approximately 15 percent of Americans. High-frequency hearing loss can be imperceptible when listening in quiet environments. However, in complex noisy environments, individuals can severely suffer from an inability to resolve speech. This is despite having normal audiometric thresholds in the low-frequency range within which speech signals are contained. There are several factors that could contribute to speech intelligibility difficulties that are imperceptible with typical hearing tests. These include impaired temporal encoding at the auditory nerve and the downstream sequelae of peripheral damage in the central auditory pathway. The goal of this study is to assess how a set of physiological measures of auditory/neural processing map onto suprathreshold hearing outcomes.

In a previous study, significant improvements in speech intelligibility have resulted from training on an immersive video game. The game uses a closed-loop audiomotor interface design that reinforces sensory-guided feedback. As a control, an auditory memory training game has been developed to replicate user expectations and procedural learning. In this study, an audiomotor game and control game will be used as mechanisms through which to track changes to physiological and perceptual biomarkers in a high frequency hearing loss cohort and a matched normal hearing cohort. Tests will be run pre-training, post- training, and at a follow-up point.

Eligibility Criteria:
Inclusion Criteria:

* High frequency hearing loss subjects - Thresholds of 15 dB HL or less for 0.25-2 kHz. Thresholds of 30-60 dB HL from 3-8 kHz.
* Normal hearing subjects - Thresholds of 15 dB HL or less from 0.5-8 kHz.
* Thresholds between left and right ears symmetric within 10 dB for all frequencies.
* Native English speakers.

Exclusion Criteria:

* Conductive hearing loss (as assessed by audiologist).
* Active otologic disease (as assessed by audiologist).
* Significant cognitive decline (Montreal Cognitive Assessment score \> 25).
The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine

To measure the magnitude and persistence of the antibody response to a booster dose of Hib conjugate vaccine given between 9 months and 4 years of age to UK children who had completed primary immunisation with 3 doses of Hib vaccine given at 2/3/4 months of age either as a combined D/T/wholecellpertussis/Hib or D/T/acellularpertussis/Hib vaccine.


Eligibility Criteria:
Inclusion Criteria:

* Written informed consent from parent or legal guardian of the infant or child
* Age \>= 9 months and \<4 years at recruitment
* Eligible to receive a single dose of Hib vaccine as per the UK schedule
* Receipt of three doses of Hib vaccine in infancy

Exclusion Criteria:

* History of Hib infection
* History of severe local reaction that can be confidently related to a prior Hib immunisation
* Deferral of vaccination if acute illness and/or temperature \>38C on day of vaccination
Oral Progesterone for Prevention of Miscarriage in Threatened Abortion

This study evaluates the effectiveness of oral dydrogesterone in preventing miscarriage in threatened abortion. Half of participants will receive oral dydrogesterone, while the other half will receive oral placebo.


Eligibility Criteria:
Inclusion Criteria:

* singleton pregnancy with gestational age 6 - 20 weeks
* threatened abortion
* confirmed intrauterine pregnancy with a viable fetus by ultrasound

Exclusion Criteria:

* history of recurrent miscarriage
* having endocervical polyp
* having infection such as pneumonia, pyelonephritis, septicemia
* having autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis
* having cancer
* having coagulation defect
* allergy to dydrogesterone
The Effect of Teaching HIV-Infected Patients About HIV and Treatment

The purpose of this study is to see if an HIV-education course can help under-represented, HIV-infected patients. This study examines the areas of faithfulness to drug regimen, level of HIV in the blood, and health status.

Following initial screening, eligible patients are treated with open-label Combivir plus abacavir for 24 weeks. Patients are randomized to undergo the education intervention, Tools for Health and Empowerment (T.H.E.) course plus counseling, or routine counseling only (control group). Measurements and evaluations for assessment of immunologic effects, adherence, and health outcomes are performed at entry (Day 1) and at Weeks 2, 5, 8, 12, 16, and 24.

Eligibility Criteria:
Inclusion Criteria

Patients must have:

* Documented and confirmed HIV infection.
* Limited or no experience with antiretrovirals.
* CD4+ lymphocyte cell count of 50 cells/mm3 or more 14 days prior to study drug administration.
* HIV-1 plasma RNA above 40 copies/ml and less than 100,000 copies/ml within 14 days prior to study drug administration.
* Ability to read, comprehend, and record information in fifth-grade English.
* Ability to attend the 4 sessions of T.H.E. course on Weeks 1-4.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* Patients suffering from a serious medical condition such as diabetes, congestive heart failure, cardiomyopathy, or other cardiac dysfunction which would compromise the safety of the patient.
* Malabsorption syndrome or other gastrointestinal dysfunction which may interfere with drug absorption or render the patient unable to take oral medication.
* Acute or chronic active hepatitis.

Concurrent Treatment:

Excluded:

Treatment with foscarnet or other agents with required documented activity against HIV-1 in vitro.

Patients with the following prior conditions are excluded:

* A clinical diagnosis of AIDS, according to the 1993 Centers for Disease Control (CDC) AIDS surveillance definition. (CD4 cell counts below 200 cells/mm3 will not be considered AIDS-defining.)
* History of allergy to any study drug.

Prior Medication:

Excluded:

* History of antiretroviral use. Patients with a history of sequential nucleoside monotherapy will be excluded, as will patients with a total antiretroviral history exceeding 6 months.
* Required treatment with immunomodulating agents, such as systemic corticosteroids, interleukins, vaccines, or interferons, within 4 weeks prior to study entry, or an HIV immunotherapeutic vaccine within 3 months prior to entry. Asthmatic patients using inhaled corticosteroids are eligible for enrollment.

Prior Treatment:

Excluded:

Radiation therapy or cytotoxic chemotherapeutic agents received within 4 weeks prior to entry.

Risk Behavior:

Excluded:

Current alcohol or illicit drug use which may interfere with the ability to comply with dosing schedule and protocol evaluation and assessment.
Frequent Activity Snacks Breaks

There is a growing health burden in Sweden and Europe arising from the interrelated sequelae of metabolic disorders comprising impaired glucose tolerance (IGT), obesity and T2DM. Obesity and inactivity are the main drivers of IGT and T2DM and are responsible for up to 8% of health costs and 13% of deaths in Europe, with the risk of co-morbidities rising in parallel with increasing body weight. IGT and T2DM are the paradigm of inactivity-related disorders: the majority of people who have IGT or T2DM are overweight and inactive, with up to 80% being obese. A recent meta-analysis of 42 studies concluded that sedentary time was independently associated with a greater risk of T2D, all-cause mortality, cardiovascular disease incidence and mortality, and cancer incidence and mortality (breast, colon, colorectal, endometrial and epithelial ovarian cancers) (Ann Intern Med. 2015;162:123-32). A recent systematic review of trials published up to April 2014 identified 16 separate studies and concluded that there is considerable evidence of the positive effects of breaking up prolonged sitting time with light-intensity ambulatory physical activity and standing on postprandial metabolic parameters, including glucose, insulin and triglyceride levels (Med Sci Sports Exerc. 2015:47:2053-61). However, to date, all of the published experimental trials describing the beneficial effects of breaking up sitting time on metabolic risk markers have been restricted to acute exposure periods (1-5 days). We will perform a RCT intervention study, which examines the efficacy (clinically relevant responses) and practical implementation of low-impact training in sedentary obese individuals during the day.


Eligibility Criteria:
Inclusion Criteria:

* Sedentary lifestyle,
* BMI 30-40 kg/m2

Exclusion Criteria:

* Unable to read Swedish (for informed consent),
* anticoagulant therapy,
* unability to perform intervention
The Impact of Coronary Chronic Total Occlusion Percutaneous Coronary Intervention on Culprit Vessel Physiology

Following successful CTO PCI, a multitude of physiological and anatomical changes take place. Contemporary techniques such as dissection/re-entry or lumen-lumen wiring may influence the immediate and longer term follow up of these features. It is not known whether changes in this level of physiology and anatomy in the context of CTO vessels correlate with each other, or with quality of life and exercise capacity.

This study aims to take physiological measurements of absolute coronary flow, resistance and pressure and intra-coronary imaging immediately after successful CTO PCI. The investigators will relate these to each other and to the method of revascularisation, comparing changes in these groups at three months follow up.

QoL measurements, and exercise testing will be carried out to see if there is a relationship between physiological and anatomical changes with exercise capacity and quality of life.

Results from this study could shed light on optimisation of CTO PCI procedural and clinical outcomes.

Following successful chronic total occlusion (CTO) percutaneous coronary intervention (PCI), a multitude of physiological and anatomical changes take place. Contemporary techniques such as dissection/re-entry or lumen-lumen wiring may influence the immediate and longer term follow up of these features. It is not known whether changes in this level of physiology and anatomy in the context of CTO vessels correlate with each other, or with quality of life and exercise capacity.

This study aims to take physiological measurements of absolute coronary flow, resistance and pressure and intra-coronary imaging immediately after successful CTO PCI. The investigators will relate these to each other and to the method of revascularisation, comparing changes in these groups at three months follow up.

Quality of life measurements, and exercise testing will be carried out to see if there is a relationship between physiological and anatomical changes with exercise capacity and quality of life.

Results from this study could shed light on optimisation of CTO PCI procedural and clinical outcomes.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age
* Presence of a coronary chronic total occlusion (CTO) scheduled for elective percutaneous coronary angioplasty (PCI)
* Evidence of viability in the CTO Territory

Exclusion Criteria:

* \< 18 year of age
* Unable to give informed consent
* Known severe chronic kidney disease (creatinine clearance ≤30 mL/min), unless the patient is on dialysis
* Unable to receive antiplatelets or periprocedural anticoagulation
* Contraindications to adenosine
* Any study lesion characteristic resulting in the expected inability to deliver FD-OCT catheter at the distal vessel post CTO PCI (e.g. moderate or severe vessel calcification or tortuosity)
* Pregnancy, planning pregnancy during study period, or breastfeeding